First Manhattan’s Sarepta Therapeutics SRPT Stock Holding History

First Manhattan’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-900	Closed	-$136K	–	1400
2019 Q2	$136K	Hold	900	–	–	﹤0.01%	771
2019 Q1	$107K	Buy	+900	New	+$116K	﹤0.01%	817
2018 Q1	–	Sell	-1,000	Closed	-$55K	–	1462
2017 Q4	$55K	Buy	+1,000	New	+$53K	﹤0.01%	984
2016 Q3	–	Sell	-3,000	Closed	-$57K	–	1454
2016 Q2	$57K	Buy	3,000 +1,000	+50%	+$18.5K	﹤0.01%	930
2016 Q1	$39K	Buy	+2,000	New	+$34.9K	﹤0.01%	966

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

First Manhattan's SRPT Position: Q3 2019 in Review

First Manhattan sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 900 shares — an estimated $136K sold.

First Manhattan first reported a position in SRPT in Q1 2016 and held it in 5 quarters. The position peaked at $136K in Q2 2019. 340 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

First Manhattan reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
First Manhattan sold 900 Sarepta Therapeutics shares in Q3 2019, an estimated $136K.
First Manhattan first reported a position in Sarepta Therapeutics in Q1 2016 and held it in 5 quarters.
First Manhattan's Sarepta Therapeutics position peaked at $136K in Q2 2019.
340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on First Manhattan's 13F filing for Q3 2019, filed 13 Nov 2019.